Abstract
Prostate-specific antigen (PSA) screening for prostate cancer is now widespread in the United States among men of all ages (1). Although prostate cancer mortality has fallen in the United States since the onset of widespread screening, a relationship between screening and the decline in mortality has not been proven.

This publication has 11 references indexed in Scilit: